基线体成分与GEP-NETs早期PRRT结局的探索性分析
该回顾性分析纳入301例接受PRRT的GEP-NETs患者,评估L3/L4水平CT体成分与早期SSTR-PET进展的关联。早期进展发生率为8.0%,传统体成分参数与早期进展无关;基线肌脂肪变性仅8例,单因素分析显示名义关联,但经多重检验校正后不显著。结论为探索性,不支持肌脂肪变性用于个体风险分层。
要点
- 传统体成分参数与PRRT后早期PET进展无关联。
- 基线肌脂肪变性仅8例,校正后与早期进展的关联不显著。
- 结果属探索性,不能确立肌脂肪变性的临床效用。
核心结论
- 传统体成分参数与PRRT后早期PET进展无关。
- 基线肌脂肪变性与早期进展仅呈名义关联,校正后不显著,结果属探索性。
研究设计与样本
- 回顾性分析筛查321例接受PRRT的患者,主要终点在301例中可评估。
- 体成分参数在L3/L4水平CT上评估,肌脂肪变性采用BMI校正的腰大肌衰减截止值定义。
主要发现
- 早期PET进展发生在24/301例患者(8.0%)。
- 基线肌脂肪变性仅8/301例(2.7%),单因素分析OR 7.8(95%CI 1.74-34.78;p=0.0073)。
- Benjamini-Hochberg校正后FDR调整p=0.1073,关联不显著。
- 基线校正模型中肌脂肪变性仍呈名义关联(OR 8.1,95%CI 1.69-38.75;p=0.0090)。
- 额外纳入完成PRRT周期数的探索性模型中关联减弱(OR 5.7,95%CI 0.97-32.86;p=0.0538)。
临床怎么用
- 传统体成分参数不应用于PRRT后早期进展的风险分层。
- 肌脂肪变性的关联证据不足,需进一步研究验证。
局限性
- 肌脂肪变性仅8例,样本量小。
- 多重检验校正后关联不显著。
- 结果为探索性、假设生成性,未确立临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Early progression after PRRT occurs in a subset of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Associations between body composition and early PET-based progression after PRRT were assessed. METHODS: In this retrospective analysis, 321 patients undergoing PRRT were screened. Body composition parameters were assessed on the CT component at the L3/L4 level. Myosteatosis was defined using BMI-adjusted psoas muscle attenuation cut-offs. The primary endpoint was early SSTR-targeted PET-based progression after up to four consecutive PRRT cycles, dichotomized as progressive disease versus disease control, which was available in 301 patients. RESULTS: Early PET-based progression occurred in 24/301 patients (8.0%). Traditional quantity-based body composition parameters were not associated with early progression. Baseline myosteatosis was present in only 8/301 patients (2.7%) and showed a nominal association with early progression in univariable analysis (OR 7.8, 95% CI 1.74-34.78; p = 0.0073), but this association did not remain significant after Benjamini-Hochberg correction for multiple testing (FDR-adjusted p = 0.1073). In a separately specified baseline-adjusted model, myosteatosis remained nominally associated with early progression (OR 8.1, 95% CI 1.69-38.75; p = 0.0090). In an exploratory model additionally including the number of completed PRRT cycles as a post-baseline treatment-exposure variable, the association was attenuated and narrowly missed conventional statistical significance (OR 5.7, 95% CI 0.97-32.86; p = 0.0538). CONCLUSION: Traditional quantity-based body composition parameters were not associated with early PET-based progression after PRRT. Although baseline myosteatosis showed a nominal association with early progression, this finding was based on only eight patients and did not remain significant after correction for multiple testing. The results should therefore be regarded as exploratory and hypothesis-generating and do not establish clinical utility of myosteatosis for individual risk stratification.
引用
- Dema E, Dascalescu C, Holzgreve A, et al. Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis. Eur J Nucl Med Mol Imaging. 2026. PMID: 42749936. doi:10.1007/s00259-026-08182-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。